0:03
Hi, David Lou here on the last day of ACR Convergence 2026, wrapping up some really interesting stuff for RheumNow.
0:14
I wanted to talk a little bit about GLP-1 receptor agonists and their therapy in general.
0:20
I think it's been a fascinating meeting for that.
0:25
We've seen really gains that we haven't expected to see. It's been really exciting like that.
0:31
If you go back though, I think a lot of this kicked off earlier this year with the TOGETHER PsA data that was released by press release in January.
0:40
The full paper came out in ARD in March from 36-week data.
0:43
What is that? Well, that's ixekizumab with or without tirzepatide.
0:53
So GLP-1, GIP dual agonism — across those trying to see whether, you know, we expect to see weight loss there.
1:00
We know that increased body mass and obesity in general is associated with worse PsA, worse psoriatic arthritis outcomes.
1:11
If we combine the two, can we really get an added benefit on top of what we see with an already effective therapy like ixekizumab?
1:18
What we saw after 36 weeks — I think what we were a little bit concerned about possibly — is we saw some really early takeoff with the add-on of tirzepatide on top of ixekizumab.
1:33
You know, that added boost, and we saw it perhaps outpace weight loss, the disease activity control.
1:39
And tirzepatide, while it was definitely better than ixekizumab across the 36 weeks, just started to see a plateau from 24 weeks to 36 weeks, and there's a question as to what would happen after that — knowing full well it was a 52-week trial.
1:58
Very glad to get that 36-week time point early, but at 52 weeks we weren't sure what was going to happen.
2:04
Until this meeting, where we saw in abstract 2942 that actually the 52-week data was even more impressive.
2:13
What we saw is the ixekizumab arm itself just tail off slightly — and you know, maybe that relates to the underlying population.
2:21
But then you saw from there that while at 36 weeks there was a 33 to 20 difference, at 52 weeks we saw a 43 to 15 difference. So that gap widened out substantially.
2:36
I think this is game-changing fundamentally.
2:38
I think if we had any question that GLP-1 targeting had a role in the future of psoriatic arthritis, this has really put that to bed.
2:51
There's still going to be questions about whether this is modifying the underlying disease or this is just mechanical offloading and changing — whether it's all related to weight loss and that maybe all weight loss relates to this.
3:05
All of that is a little bit of a theoretical moot argument, because we've struggled for so long to actually operationalize weight loss.
3:16
We have therapies which can be the backbone of a comprehensive weight loss program.
3:21
Now we've had increased attention to weight loss, and now it's actually possible, and we've seen very clear data now that when you add it
3:31
on top of effective DMARDs you can get real benefits and gains in psoriatic arthritis that really we were struggling to unlock before — especially
3:39
in the right population.
3:41
Now that's going to be the question: who are we using this in, at what stage are we using this?
3:46
All of that will come in due course. But I think we'll look back at ACR 2026 and say this is the meeting where we saw the TRIUMPH data, the retatrutide data, and then we saw the completion of TOGETHER PsA with tirzepatide, and we'll look back and say this was the start of something big.
4:11
For all of the coverage from RheumNow ongoing, you know where to go — RheumNow.com.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.